Nasdaq Expands Analytics Hub -- Adds Four Data Sets with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
150
Nasdaq Expands Analytics Hub -- Adds Four Data Sets with New Signals

NEW YORK, July 20, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ ), a leading provider of real-time market data and analytics to large institutions, financial professionals, and retail investors, announced the addition of four new data sets to the Nasdaq Analytics Hub . The Nasdaq Analytics Hub debuted in May 2017 to address the growing needs of the buy-side to gain access to potential new trading and investment signals derived from the growing number of structured and unstructured data sets. The addition of these four new data sets both broadens and deepens the high value content within the Nasdaq Analytics Hub, providing insights from corporate filings, combinations of fundamental and technical factors, and two different approaches for long and short investing.

“Nasdaq is continuing to bring innovation and change to the buy-side through products like the Analytics Hub,” said Terry Wade, Senior Vice President, Nasdaq. “Collaborating with innovative partners to provide more signals will help provide more clarity around investing in today’s markets and will serve as a highly valuable and informative resource for our client base.”

Market participants will benefit from the data sets because of the new signals designed for the most common buy-side holding periods and the most common corporate filings. These sets will allow firms to understand and predict underlying movement for the securities in their portfolios and models.

The new data sets are with the following partners:

  • 280first (Corporate Filings)  delivers data focused on changes in SEC financial filings, scoring the language to create signals to reflect changes in a firm’s plans, strategies, and risks.
  • Lucena Research provides two new data sets based on artificial intelligence and algorithmic multi-factor ensemble voting to forecast equities’ price predictions.
  • PredictWallStreet harnesses the collective intelligence of online retail investors, and provides daily trading signals on US equities, ADRs, and ETFs based on this retail sentiment.

“We’re honored to partner with Nasdaq to help the investment community make more informed, smarter decisions,” said Zhiping Zhao, co-Founder of 280first. “Adding our product’s actionable information from corporate filing data will become a highly valued and critical component of the Nasdaq Analytics Hub.”   

To learn more about Nasdaq Analytics Hub, please visit our website or click here and a member of Nasdaq’s team will contact you. 

About Nasdaq

Nasdaq (Nasdaq: NDAQ ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit:  http://business.nasdaq.com

About 280first

280first was founded in 2014 by a team led by Zhiping (Ping) Zhao, Ph.D., a distinguished senior research analyst with deep knowledge and experience in both equity and credit arenas. The 280first platform uses sophisticated data analytics in combination with experienced analysts to expose and score noteworthy highlights signaling a company’s internal deliberations, upcoming material events and disclosures. Purpose-built to expand the reach and efficacy of investment professionals, the company offers a series of high value solutions for financial services markets.  

About PredictWallStreet

Founded in 2005, PredictWallStreet is the leading online stock prediction community dedicated to tracking retail investor sentiment in the stock market. Community members make stock predictions, track their own success rates, and compare their predictions with others’ to improve their investment strategies. PredictWallStreet aggregates predictions to generate free, daily community sentiment graphs and forecasts. PredictWallStreet has processed millions of investor predictions making it a reliable, and the longest standing, source of retail investor sentiment. Go to www.PredictWallStreet.com .

About Lucena Research:

Co-founded in 2014 by entrepreneur and technologist CEO Erez Katz and machine learning and artificial intelligence expert, Chief Science Officer Tucker Balch, Ph.D, Lucena Research partners with data providers and develops algorithms that can validate and enhance investment strategies through advanced analytics of big data. Lucena’s cloud-based artificial intelligence tools create a research, discovery and analysis partnership that enables wealth managers to refine their strategies with confidence and unprecedented visibility into the data, revealing actionable insight. Enabling solutions that are unique to each user, Lucena allows for personalized analysis and strategic recommendations. As an industry-leader in financial machine intelligence, Lucena applies science to finance and provides solutions for experienced clients in financial management worldwide.  Partner with experts in predictive analytics at Lucenaresearch.com

NDAQG

Nasdaq Media Contact: Christine Barna 646 441 5310 christine.barna@nasdaq.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading